Is CMPI or EPRT a better dividend investment in 2026?

CMPI currently yields 19.05% with a 5% 5-year dividend growth rate. EPRT yields 3.92% with 5% growth. The better choice depends on your goal: CMPI offers higher current income.

What is the dividend yield difference between CMPI and EPRT?

CMPI has a forward dividend yield of 19.05% ($2.00/share annually). EPRT yields 3.92% ($1.21/share annually). The yield gap is 15.13 percentage points.

Home › Compare › CMPI vs EPRT

CMPI vs EPRT: Dividend Comparison 2026

CMPI yields 19.05% · EPRT yields 3.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CMPI wins by $5.5K in total portfolio value

INVESTMENT

TIME HORIZON10 years

CMPI

● Live price

19.05%

Share price

$10.50

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$68.9K

Annual income

$6,079.53

Full CMPI calculator →

EPRT

● Live price

3.92%

Share price

$30.77

Annual div

$1.21

5Y div CAGR

29%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$63.4K

Annual income

$12,840.73

Full EPRT calculator →

Portfolio growth — CMPI vs EPRT

📍 CMPI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CMPI	EPRT
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CMPI + EPRT cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CMPI pays

EPRT pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMPI

Annual income on $10K today (after 15% tax)

$1,619.05/yr

After 10yr DRIP, annual income (after tax)

$5,167.60/yr

EPRT

Annual income on $10K today (after 15% tax)

$332.87/yr

After 10yr DRIP, annual income (after tax)

$10,914.62/yr

At 15% tax rate, EPRT beats the other by $5,747.02/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMPI + EPRT for your $10,000?

CMPI: 50%EPRT: 50%

100% EPRT50/50100% CMPI

Portfolio after 10yr

$66.1K

Annual income

$9,460.13/yr

Blended yield

14.31%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

CMPI

Analyst Ratings

Buy

Hold

Consensus: Buy

EPRT

Analyst Ratings

Strong

Buy

Hold

Sell

Consensus: Buy

Price Target

$35.50

+15.4% upside vs current

Range: $33.00 — $37.00

Altman Z

1.8

Piotroski

5/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMPI buys

EPRT buys

No recent congressional trades found for CMPI or EPRT in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCMPIEPRT

Forward yield	19.05% ✓	3.92%
Annual dividend / share	$2.00 ✓	$1.21
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	29% ✓
Portfolio after 10y	$68.9K ✓	$63.4K
Annual income after 10y	$6,079.53	$12,840.73 ✓
Total dividends collected	$38.2K ✓	$37.9K
Payment frequency	quarterly	quarterly
Sector	Stock	REIT
Analyst consensus	Buy	Buy

Year-by-year: CMPI vs EPRT ($10,000, DRIP)

Year	CMPI Portfolio	CMPI Income/yr	EPRT Portfolio	EPRT Income/yr	Gap
1← crossover	$12,605	$1,904.76	$11,205	$505.18	+$1.4K → CMPI
2	$15,731	$2,243.84	$12,672	$682.46	+$3.1K → CMPI
3	$19,449	$2,617.14	$14,490	$930.48	+$5.0K → CMPI
4	$23,835	$3,024.07	$16,786	$1,282.69	+$7.0K → CMPI
5	$28,967	$3,463.51	$19,753	$1,791.56	+$9.2K → CMPI
6	$34,928	$3,933.88	$23,677	$2,541.64	+$11.3K → CMPI
7	$41,806	$4,433.18	$29,008	$3,672.99	+$12.8K → CMPI
8	$49,692	$4,959.03	$36,463	$5,425.08	+$13.2K → CMPI
9	$58,679	$5,508.79	$47,238	$8,221.57	+$11.4K → CMPI
10	$68,866	$6,079.53	$63,385	$12,840.73	+$5.5K → CMPI

CMPI vs EPRT: Complete Analysis 2026

CMPI — Stock

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.

Full CMPI Calculator →

EPRT — REIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →

📬

Get this CMPI vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMPI vs SCHD CMPI vs JEPI CMPI vs O CMPI vs KO CMPI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.